The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer
- 1 September 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 91 (2) , 157-167
Abstract
No abstract availableKeywords
Funding Information
- EU project Pro-KinaseResearch (LSHB-CT-2004-503467)
This publication has 44 references indexed in Scilit:
- The Novel Akt Inhibitor API-1 Induces c-FLIP Degradation and Synergizes with TRAIL to Augment Apoptosis Independent of Akt InhibitionCancer Prevention Research, 2012
- Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer TreatmentMolecular Cancer Therapeutics, 2011
- Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonistApoptosis, 2010
- Activation of the Akt Survival Pathway Contributes to TRAIL Resistance in Cancer CellsPLOS ONE, 2010
- TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5Molecular Cancer Research, 2008
- The TRAIL apoptotic pathway in cancer onset, progression and therapyNature Reviews Cancer, 2008
- Mcl-1: A Gateway to TRAIL SensitizationCancer Research, 2008
- The promise of TRAIL—potential and risks of a novel anticancer therapyJournal of Molecular Medicine, 2007
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2British Journal of Cancer, 2003